456 related articles for article (PubMed ID: 28775119)
41. BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Visentin A; Imbergamo S; Scomazzon E; Pravato S; Frezzato F; Bonaldi L; Pizzi M; Vio S; Gregianin M; Burei M; Facco M; Semenzato G; Piazza F; Trentin L
Br J Haematol; 2019 Apr; 185(1):193-197. PubMed ID: 29974955
[No Abstract] [Full Text] [Related]
42. Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
Ma S; Chan RJ; Gu L; Xing G; Rajakumaraswamy N; Ruzicka BB; Wagner-Johnston ND
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):e432-e448. PubMed ID: 33516721
[TBL] [Abstract][Full Text] [Related]
43. Management of Ibrutinib Toxicities: a Practical Guide.
Lasica M; Tam CS
Curr Hematol Malig Rep; 2020 Jun; 15(3):177-186. PubMed ID: 32415406
[TBL] [Abstract][Full Text] [Related]
44. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
Tobinai K; Ogura M; Ishizawa K; Suzuki T; Munakata W; Uchida T; Aoki T; Morishita T; Ushijima Y; Takahara S
Int J Hematol; 2016 Jan; 103(1):86-94. PubMed ID: 26588924
[TBL] [Abstract][Full Text] [Related]
45. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
[No Abstract] [Full Text] [Related]
46. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Tran PN; O'Brien S
Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
[TBL] [Abstract][Full Text] [Related]
47. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):1003-1005. PubMed ID: 29720040
[TBL] [Abstract][Full Text] [Related]
48. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Roskoski R
Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927
[TBL] [Abstract][Full Text] [Related]
49. Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.
Louie CY; DiMaio MA; Matsukuma KE; Coutre SE; Berry GJ; Longacre TA
Am J Surg Pathol; 2015 Dec; 39(12):1653-60. PubMed ID: 26426383
[TBL] [Abstract][Full Text] [Related]
50. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
51. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Brown JR
Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
[TBL] [Abstract][Full Text] [Related]
52. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Titus-Rains KS; Brown JN; Hammond JM
J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
[TBL] [Abstract][Full Text] [Related]
53. No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
Barrientos JC; Hillmen P; Salles G; Sharman J; Stilgenbauer S; Gurtovaya O; Xing G; Ruzicka B; Bhargava P; Ghia P; Pagel JM
Leuk Lymphoma; 2021 Apr; 62(4):837-845. PubMed ID: 33297794
[TBL] [Abstract][Full Text] [Related]
54. Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
Chung C; Lee R
Pharmacotherapy; 2014 Dec; 34(12):1298-316. PubMed ID: 25355689
[TBL] [Abstract][Full Text] [Related]
55. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
[TBL] [Abstract][Full Text] [Related]
56. Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
Foluso O; Glick A; Stender M; Jaiyesimi I
Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):63-9. PubMed ID: 26775273
[TBL] [Abstract][Full Text] [Related]
57. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
Cuneo A; Barosi G; Danesi R; Fagiuoli S; Ghia P; Marzano A; Montillo M; Poletti V; Viale P; Zinzani PL
Hematol Oncol; 2019 Feb; 37(1):3-14. PubMed ID: 30187496
[TBL] [Abstract][Full Text] [Related]
58. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Tang CPS; McMullen J; Tam C
Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
[TBL] [Abstract][Full Text] [Related]
59. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
60. Idelalisib-associated Colitis: Histologic Findings in 14 Patients.
Weidner AS; Panarelli NC; Geyer JT; Bhavsar EB; Furman RR; Leonard JP; Jessurun J; Yantiss RK
Am J Surg Pathol; 2015 Dec; 39(12):1661-7. PubMed ID: 26448188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
